EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome



Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome



Blood 100(13): 4337-4343



Veno-occlusive disease (VOD) is the most common regimen-related toxicity accompanying stem cell transplantation (SCT). Severe VOD complicated by multisystem organ failure (MOF) remains almost uniformly fatal. Preliminary experience with defibrotide (DF), a single-stranded polydeoxyribonucleotide with fibrinolytic, antithrombotic, and anti-ischemic properties, in the treatment for severe VOD has suggested safety and activity. Eighty-eight patients who developed severe VOD after SCT were treated with DF under a defined treatment plan. At diagnosis, median bilirubin was 76.95 microM (4.5 mg/dL), median weight gain was 7%, ascites was present in 84%, and abnormal hepatic portal venous flow was present in 35%. At DF initiation, median bilirubin had increased to 215.46 microM (12.6 mg/dL), and MOF was present in 97%. DF was administered intravenously in doses ranging from 5 to 60 mg/kg per day for a median of 15 days. No severe hemorrhage or other serious toxicity related to DF was reported. Complete resolution of VOD was seen in 36%, with 35% survival at day +100. Predictors of survival included younger age, autologous SCT, and abnormal portal flow, whereas busulfan-based conditioning and encephalopathy predicted worse outcome. Decreases in mean creatinine and plasminogen activator inhibitor 1(PAI-1) levels during DF therapy predicted better survival. The complete response rate, survival to day +100, and absence of significant DF-associated toxicity in this largest patient cohort reported to date confirm the results of earlier studies. Certain features associated with successful outcome may correlate with DF-related treatment effects, and prospective evaluation of DF therapy for severe VOD should allow better definition of predictors of response or failure.

(PDF emailed within 0-6 h: $19.90)

Accession: 011022112

Download citation: RISBibTeXText

PMID: 12393437

DOI: 10.1182/blood-2002-04-1216



Related references

Multi-institutional phase II, randomized dose finding study of defibrotide in patients with severe veno-occlusive disease and multi-system organ failure post stem cell transplantation Promising response rate without significant toxicity in a high risk population. Blood 98(11 Part 1): 853a, November 16, 2001

Multi-institutional emergency use of defibrotide in 75 pts post SCT with severe VOD and multi-system organ failure Response without significant toxicity in a high risk population. Blood 96(11 Part 1): 585a, November 16, 2000

Defibrotide Appears Effective and Safe in a Phase II, Randomized Study of Patients with Severe Veno-Occlusive Disease and Multi-System Organ Failure Post Stem Cell Transplantation. Blood 100(11): Abstract No 414, November 16, 2002

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 92(3): 737-744, 1998

Defibrotide is effective in the treatment of severe veno-occlusive disease and multi-system organ failure post stem cell transplantation Results of a phase II, multicenter, randomized Study. Blood 102(11): 193a, November 16, 2003

Treatment of severe veno-occlusive disease with defibrotide Compassionate use results in efficacy without significant toxicity in a high risk population. Blood 90(10 SUPPL 1 PART 1): 252A, Nov 15, 1997

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127(13): 1656-1665, 2016

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biology of Blood and Marrow Transplantation 16(7): 1005-1017, 2011

Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation. Clinical Drug Investigation 34(12): 895-904, 2015

Pre-emptive therapy with defibrotide to prevent severe veno-occlusive disease after stem cell transplantation. Blood 102(11): 466a, November 16, 2003

Veno-occlusive disease and multi-organ failure following actinomycin-D treatment Clinical characteristics and predictive factors. JPGN 31(Supplement 2): S51, 2000

Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. Clinical Transplantation 22(6): 837-841, 2008

Veno-occlusive disease of the liver after autologous and allogeneic hematopoietic stem cell transplantation in children Incidence, risk factors and outcome. Blood 94(10 SUPPL 1 PART 1): 709a, Nov 15, 1999

Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation 10(5): 347-354, 2004

Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation-- successful treatment with high-dose methylprednisolone and defibrotide. Journal of Cancer Research and Clinical Oncology 128(3): 148-152, 2002